SCHEMBL2865232

SCHEMBL2865232

O=C(NCCc1cccs1)c1ccc2[nH]nc(-c3cc4ccccc4s3)c2c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 7/20 0.53
MAPK3 P27361 3/20 0.53
CYP1A2 P05177 1/20 0.51
TTK P33981 1/20 0.50
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
LMNA P02545 1/20 0.48
MAPK10 P53779 1/20 0.47
TAAR1 Q96RJ0 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FLT3 P36888 1/20 0.45
MAPKAPK2 P49137 1/20 0.44
PSMD14 O00487 1/20 0.43
STAMBP O95630 1/20 0.43
COPS5 Q92905 1/20 0.43
NAMPT P43490 1/20 0.42
CSNK1D P48730 1/20 0.42
ROCK2 O75116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335922 0.82 CYP1A2 (0.41) MAPK1MAPK3CYP1A2NPC1RAB9A
SCHEMBL2855817 0.80 MAPK10 (0.58) TTKNPC1RAB9AMAPK10SMN1; SMN2
SCHEMBL4339889 0.80 BRD4 (0.46) CYP1A2NPC1RAB9ALMNAMAPK10
SCHEMBL2860415 0.77 MAPK10 (0.54) MAPK1MAPK3MAPK10MAPKAPK2
SCHEMBL5380014 0.76 MAPK10 (0.56) MAPK1MAPK3TTKMAPK10FLT3
SCHEMBL2862809 0.76 RAB9A (0.50) MAPK1RAB9ALMNAMAPK10SMN1; SMN2
SCHEMBL5377524 0.76 MAPK10 (0.53) MAPK1MAPK10FLT3MAPKAPK2
SCHEMBL4335941 0.74 MAPT (0.49) MAPK1CYP1A2TTKNPC1RAB9A
SCHEMBL1627170 0.74 NPC1 (0.48) MAPK1MAPK3CYP1A2TTKNPC1
SCHEMBL16866589 0.73 RAB9A (0.64) CYP1A2NPC1RAB9ALMNATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK1 1/4885MAPK3 2/4885CYP1A2 379/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 MAPK1 1/4885MAPK3 3/4885CYP1A2 444/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK1 1/4885MAPK3 2/4885CYP1A2 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.